6833 — Sinco Pharmaceuticals Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapValue Trap

Market Cap
HK$376.08m
Enterprise Value
HK$370.89m
Revenue
CNY2.82bn

Annual income statement for Sinco Pharmaceuticals Holdings, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,050	2,024	2,272	2,540	2,821
Cost of Revenue
Gross Profit	274	365	306	323	300
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,905	1,828	2,154	2,426	2,706
Operating Profit	145	197	118	114	116
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	136	167	99.3	99.9	98.9
Provision for Income Taxes
Net Income After Taxes	118	135	69.5	42.4	42
Minority Interest
Net Income Before Extraordinary Items
Net Income	118	135	69.5	42.4	42
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	118	135	69.5	42.4	42
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.07	0.078	0.034	0.021	0.021
Dividends per Share